Bicycle Therapeutics reveals new CFO

pharmafile | August 2, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  Bicycle Therapeutics, biotech, drugs, pharma, pharmaceutical 

Bicycle Theapeutics, a biotech that is developing its bicyclic peptide product platform, has announced the appointed of Lee Kalowski as its Chief Financial Officer. Kalowski arrives at the company with a broad range of experience, including working directly in the biotech and pharma industries.

Kalowski was responsible, in his last position, for Tokai Pharmaceutical initial $105 million public offering but was let go from the position in August 2016. He had been without a position until now but Bicycle has brought him to the company as part of a development push, coming not long after raising £40 million as part of a Series B funding.

Kalowski has further pharma experience from his time working in Janssen, as part of its mergers and acquisitions division. He was also Vice President of Global Biotechnology Research at Credit Suisse.

“Bicycle has pioneered a revolutionary platform that has generated a new class of drugs designed to target diseases more effectively,” said Kalowski, after his appointment. “I am thrilled to be joining the company as the pipeline continues to expand and as the company transitions into a clinical-stage biotech company.”

“We are delighted to welcome Lee to the Bicycle team at this exciting time for our company,” said Dr. Kevin Lee, CEO of Bicycle Therapeutics. “He brings a wealth of experience working with biotech companies at all stages of their evolution, both as a Wall Street research analyst and as a public company CFO, and his insights will prove invaluable as we continue to grow our business, expand our pipeline and move our lead candidate, BT1718, into clinical development.”